Intangible Assets

GLMD lacks evidence of durable brand, patent, or regulatory exclusivity that would let it command peer-leading pricing power versus larger biotech peers, so any intangible advantage appears limited and non-differentiated.

Negative TTM ROIC and ROCE indicate the company is not converting any protected know-how into economic returns, which is weaker than peers with approved products or deeper IP portfolios.

No disclosed 5-year profitability or margin history in the provided metrics suggests there is no visible track record of intangibles sustaining margins better than peers over time.

Compared with established specialty pharma or biotech peers, GLMD appears to have materially less evidence of proprietary assets that would defend retention or pricing over a 5–10 year horizon.

Switching Costs

GLMD does not appear to operate a platform or embedded workflow where customers face high switching friction, so buyers can likely substitute alternatives with limited lock-in versus peers.

The negative ROIC and ROCE imply the company is not benefiting from recurring customer dependence that would normally show up as durable economic returns.

No evidence of long-duration contracts, installed-base dependence, or regulatory integration was provided, which makes switching costs look materially weaker than in peer businesses with entrenched products.

Relative to peers with approved therapies or standard-of-care positioning, GLMD appears to have little structural retention advantage that would protect margins or pricing.

Network Effects

GLMD does not show a product or ecosystem where each additional user increases value for other users, so network effects are effectively absent versus peers.

The provided metrics do not indicate scale-driven user adoption, data flywheels, or platform participation that would reinforce competitive advantage over time.

Negative capital returns are inconsistent with a self-reinforcing network that would normally support superior monetization relative to peers.

Compared with peer companies that benefit from physician, payer, or platform adoption loops, GLMD shows no visible network-based moat.

Cost Advantage

GLMD’s negative ROIC and ROCE suggest it does not currently operate with a cost structure that converts into superior unit economics versus peers.

No evidence of manufacturing scale, procurement leverage, or process efficiency was provided, so there is no clear basis for a durable cost edge.

The absence of positive margin history in the supplied data weakens any claim that GLMD can underprice peers while preserving returns.

Relative to larger biotech or specialty pharma peers, GLMD appears unlikely to have a structural cost advantage that would sustain pricing power.

Efficient Scale

GLMD does not appear to serve a niche market with limited room for multiple profitable competitors, so efficient-scale protection is not evident versus peers.

The company’s negative capital returns imply it is not capturing the economics of a constrained market structure that would typically support durable excess returns.

No evidence of regulatory bottlenecks, exclusive distribution, or capacity constraints was provided, which reduces the likelihood of efficient-scale moat durability.

Compared with peers that dominate narrow indications or specialized channels, GLMD shows little sign of operating in a market structure that naturally limits competition.

Overall Score

GLMD’s moat appears weak versus peers because the provided data show negative capital returns and no visible evidence of durable intangibles, switching costs, network effects, cost advantage, or efficient-scale protection.